SCHEMBL3979506

SCHEMBL3979506

CC(=O)Oc1ccc(C(=O)O)cc1C(=O)OC(C)(C)C

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.59
TSHR P16473 4/20 0.59
ALDH1A1 P00352 4/20 0.59
RAB9A P51151 2/20 0.59
GAA P10253 1/20 0.59
CFD P00746 2/20 0.50
HSD17B10 Q99714 5/20 0.45
PTGS1 P23219 2/20 0.45
PTGS2 P35354 2/20 0.45
HPGD P15428 2/20 0.45
ESR1 P03372 1/20 0.45
ITGB3 P05106 1/20 0.45
ITGA2B P08514 1/20 0.45
HMGB1 P09429 1/20 0.45
GGT1 P19440 1/20 0.45
BLM P54132 1/20 0.45
NAPRT Q6XQN6 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
LMNA P02545 2/20 0.44
CYP1A2 P05177 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23812308 0.87 KDM4E (0.43) KDM4ETSHRALDH1A1RAB9AGAA
SCHEMBL829131 0.81 KDM4E (0.43) KDM4ETSHRALDH1A1RAB9AGAA
SCHEMBL11563743 0.81 KDM4E (0.71) KDM4ETSHRALDH1A1RAB9AGAA
SCHEMBL7803837 0.81 KMT2A (0.47) KDM4ETSHRALDH1A1RAB9AGAA
SCHEMBL17713226 0.80 KDM4E (0.50) KDM4ETSHRALDH1A1RAB9AGAA
SCHEMBL27534696 0.80 KDM4E (0.46) KDM4ETSHRALDH1A1RAB9AGAA
SCHEMBL30638610 0.80 KDM4E (0.50) KDM4ETSHRALDH1A1RAB9AGAA
SCHEMBL23812315 0.79 CFD (0.43) KDM4ETSHRALDH1A1RAB9AGAA
SCHEMBL20928681 0.78 RXRA (0.41) KDM4ETSHRALDH1A1RAB9AGAA
SCHEMBL3982155 0.78 EGFR (0.49) KDM4EGAAPTGS2CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514452-B2 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same DAINIPPON PHARMACEUTICAL CO., LTD (JP) 2009-04-07 US disclosed
US-20050171196-A1 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2005-08-04 US disclosed
EP-1489077-A1 2-FURANCARBOXYLIC ACID HYDRAZIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 2004-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171196-A1 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same GLP1R, GCGR, GPR119 KDM4E 2769/4885TSHR 82/4885ALDH1A1 1389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.